News - Hamlet BioPharma

Jun

29

2026

Pressrelease – Lund, June 29th, 2026 – Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer

Hamlet Biopharma

|

Hamlet BioPharma, a pharmaceutical company specializing in the development of novel treatments for cancer and infectious diseases, today announces reg...

Jun

29

2026

Pressrelease – Lund, 29 Juni, 2026 – Briefglance uppmärksammar Hamlet BioPharmas samarbete med Universitetet i Iowa och potentialen för behandling av svår blåscancer

Hamlet Biopharma

|

Newsletter, Press releases

Den digitala analysplattformen Briefglance har uppmärksammat Hamlet BioPharma och samarbetet med Universitetet i Iowa kring utvecklingen av Alpha1H fö...

Jun

25

2026

Pressrelease – Lund, June 25th, 2026 – Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma today announces the successful release of the Phase III quality batch of Alpha1H for use in clinical trials of bladder cancer in Euro...

Jun

23

2026

Pressrelease – Lund, June 23rd, 2026 – Hamlet BioPharma’s monthly digital investors’ meeting on June 30th

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 30th of June 2026, at 12:00. Please click on the link below to partic...

Jun

22

2026

Press release – Lund, June 22th, 2026 – Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for ...

Jun

17

2026

Press release – Lund, June 17th, 2026 – Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma AB (publ) today conducted a pre-initiation visit at the Department of Urology at Charles University, Prague, led by Professor Marek B...

Jun

10

2026

Press release – Lund, June 10th, 2026 – Continued success for the new anti-infective therapies developed by Hamlet BioPharma

Hamlet Biopharma

|

Newsletter, Press releases

The Journal of Infectious Diseases publishes the paper “Targeting the disease response with NlpD and LytM for effective non-antibiotic treatment of ur...

Jun

08

2026

Pressrelease – Lund, 8 juni, 2026 – Utökning av Hamlet BioPharmas kliniska samarbeten med ledande amerikanskt universitet

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma AB (publ) meddelar idag att bolaget inlett ett samarbete med University of IOWA, ett amerikanskt center inom uro-onkologi med fokus p...

May

22

2026

Q3 Interim Report January – March 2026

Hamlet Biopharma

|

Financial, Newsletter, Press releases

...

May

21

2026

Press release – Lund, May 21st, 2026 – Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to the investors’ meeting to be held on the 22nd of May 2026, at 12:00. Please click on the link below to participate in ...

May

18

2026

Press release – Lund, May 18th, 2026 – Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology26

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet Biopharma, a company innovating the treatment of cancer and infections, today announced the successful granting of new patents in Japan and Ind...

Apr

23

2026

Pressrelease – Lund, April 23, 2026 – Monthly investor meeting on the 29th of April, 2026

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to the monthly digital investors’ meeting to be held on the 29th of April 2026, at 12:00. Please click on the link below ...

Mar

30

2026

Pressrelease – Lund, March 30th, 2026 – Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma AB, an innovative pharmaceutical company developing new therapies for cancer and infections, announces that the company presented its...

Mar

24

2026

Pressrelease – Lund, 24 Mars, 2026 – Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma, ett innovativt läkemedelsbolag som utvecklar nya terapier mot cancer och infektioner, meddelar att bolaget tillförs cirka 8.5 miljon...

Mar

17

2026

Pressrelease – Lund, March 17th, 2026 – Hamlet BioPharmas digital monthly investor meeting on the 18th of March

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 18th of March 2026, at 12:00. Please click on the link below to parti...

Mar

15

2026

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

Hamlet Biopharma

|

Newsletter, Press releases

Lund, 15 mars 2026, Hamlet BioPharma, ett innovativt läkemedelsbolag som utvecklar nya terapier mot cancer och infektioner, meddelar att styrelsen har...

Mar

09

2026

Nyhetsbrev – Hamlet BioPharma har undertecknat ett Letter of Intent avseende ett potentiellt kommersiellt avtal avseende Alpha 1H

Hamlet Biopharma

|

Newsletter, Press releases

Som tidigare meddelats har Hamlet BioPharma, tillsammans med det helägda dotterbolag Alpha1H BC AB (A1HB) och samarbetspartnern Linnane Pharma AB, und...

Mar

08

2026

PRESS RELEASE – Lund, March 8, 2026 – Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma AB (Hamlet), a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announces that its ...

Feb

23

2026

Nyhetsbrev – Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner

Hamlet Biopharma

|

Newsletter, Press releases

Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner Hamlet BioPharma, det innovativa ...

Feb

18

2026

Newsletter – Catharina Svanborg featured in Global Digital Women’s Magazine

Hamlet Biopharma

|

Newsletter, Press releases

Catharina Svanborg featured in Global Digital Women’s Magazine Read the interview with Hamlet BioPharma’s founder Catharina Svanborg on Femest.com, p...

Feb

13

2026

Q2 Interim Report October – December 2025

Hamlet Biopharma

|

Financial, Newsletter, Press releases

...

Feb

12

2026

PRESS RELEASE – Lund, February 12th, 2026 – Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’

Hamlet Biopharma

|

Newsletter, Press releases

This groundbreaking study introduces an entirely new approach to managing recurrent urinary tract infections. Instead of killing the bacteria, the tre...

Feb

11

2026

PRESS RELEASE – Lund, February 11th, 2026 – Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to our February investors’ meeting to be held on the 13th of February 2026, at 12:00. Please click on the link below to p...

Feb

03

2026

PRESS RELEASE – Lund, February 3rd, 2026 – Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administration technology for the peptide drug ...

Jan

27

2026

PRESS RELEASE – Lund 27 January 2026 – 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

Hamlet Biopharma

|

Newsletter, Press releases

We warmly welcome you to the Symposium on “𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿.” The invited speakers are leading international scientists with...

Jan

16

2026

PRESSRELEASE – Lund 16 January 2026 – Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics

Hamlet Biopharma

|

Newsletter, Press releases

Welcome to Hamlet BioPharma’s monthly digital meeting on January 21 at 12:00, held the same day as the Davos Summit discusses ‘’The Fragile Future of ...

Dec

18

2025

PRESSRELEASE – Lund 18 December, 2025 – The HAMLET project featured in Cancerfonden’s Christmas Campaign

Hamlet Biopharma

|

Newsletter, Press releases

The Swedish Cancer Society, Cancerfonden, is a powerful and important research support organization in Sweden. Based mainly on donations, Cancerfonden...

Dec

04

2025

Pressmeddelande – Lund 4 december, 2025 – Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte

Hamlet Biopharma

|

Newsletter, Press releases

Vid årsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 4 december 2025 fattades de beslut som beskrivs neda...

Nov

14

2025

Nyhetsbrev – FDA ger Hamlet BioPharma pivotal status för avgörande Fas III studie i blåscancer

Hamlet Biopharma

|

Newsletter, Press releases

Federal and Drug Administration i USA (FDA) har som tidigare meddelats lämnat skriftlig feedback som stöder Hamlet BioPharmas planerade Fas III‑studie...

Nov

14

2025

Q1 Interim Report July – September 2025

Hamlet Biopharma

|

Financial, Newsletter, Press releases

...

Nov

13

2025

Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.00

Hamlet Biopharma

|

Newsletter, Press releases

Klicka på länken nedan för att delta. Det går bra att ställa frågor till bolaget genom att e-posta dem till: fraga@investorstudios.se. Sändningen star...

Nov

12

2025

PRESSRELEASE – Lund 12 november, 2025 – Ny styrelsesammansättning stärker Hamlet BioPharma inför kommersialiseringsfas

Hamlet Biopharma

|

Newsletter, Press releases

Förslag ny styrelsesammansättning och ny ordförande Inför ordinarie årsstämma i Hamlet BioPharma föreslår större ägare omval av Catharina Svanborg, Ma...

Nov

10

2025

PRESS RELEASE – Lund, November 10th, 2025 – Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer

Hamlet Biopharma

|

Newsletter, Press releases

HAMLET BioPharma, a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announced it has received writt...

News:

Pressrelease – Lund, June 29th, 2026 – Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer

Pressrelease – Lund, 29 Juni, 2026 – Briefglance uppmärksammar Hamlet BioPharmas samarbete med Universitetet i Iowa och potentialen för behandling av svår blåscancer

Pressrelease – Lund, June 25th, 2026 – Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites

Pressrelease – Lund, June 23rd, 2026 – Hamlet BioPharma’s monthly digital investors’ meeting on June 30th

Press release – Lund, June 22th, 2026 – Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)

Press release – Lund, June 17th, 2026 – Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

Press release – Lund, June 10th, 2026 – Continued success for the new anti-infective therapies developed by Hamlet BioPharma

Pressrelease – Lund, 8 juni, 2026 – Utökning av Hamlet BioPharmas kliniska samarbeten med ledande amerikanskt universitet

Q3 Interim Report January – March 2026

Press release – Lund, May 21st, 2026 – Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report

Press release – Lund, May 18th, 2026 – Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology26

Pressrelease – Lund, April 23, 2026 – Monthly investor meeting on the 29th of April, 2026

Pressrelease – Lund, March 30th, 2026 – Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

Pressrelease – Lund, 24 Mars, 2026 – Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner

Pressrelease – Lund, March 17th, 2026 – Hamlet BioPharmas digital monthly investor meeting on the 18th of March

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

Nyhetsbrev – Hamlet BioPharma har undertecknat ett Letter of Intent avseende ett potentiellt kommersiellt avtal avseende Alpha 1H

PRESS RELEASE – Lund, March 8, 2026 – Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H

Nyhetsbrev – Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner

Newsletter – Catharina Svanborg featured in Global Digital Women’s Magazine

Q2 Interim Report October – December 2025

PRESS RELEASE – Lund, February 12th, 2026 – Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’

PRESS RELEASE – Lund, February 11th, 2026 – Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report

PRESS RELEASE – Lund, February 3rd, 2026 – Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

PRESS RELEASE – Lund 27 January 2026 – 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

PRESSRELEASE – Lund 16 January 2026 – Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics

PRESSRELEASE – Lund 18 December, 2025 – The HAMLET project featured in Cancerfonden’s Christmas Campaign

Pressmeddelande – Lund 4 december, 2025 – Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte

Nyhetsbrev – FDA ger Hamlet BioPharma pivotal status för avgörande Fas III studie i blåscancer

Q1 Interim Report July – September 2025

Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.00

PRESSRELEASE – Lund 12 november, 2025 – Ny styrelsesammansättning stärker Hamlet BioPharma inför kommersialiseringsfas

PRESS RELEASE – Lund, November 10th, 2025 – Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer

Pressrelease – Lund, June 29th, 2026 – Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer

Pressrelease – Lund, 29 Juni, 2026 – Briefglance uppmärksammar Hamlet BioPharmas samarbete med Universitetet i Iowa och potentialen för behandling av svår blåscancer

Pressrelease – Lund, June 25th, 2026 – Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites

Pressrelease – Lund, June 23rd, 2026 – Hamlet BioPharma’s monthly digital investors’ meeting on June 30th